Fig. 1 · Structure

Documents & Downloads

Tolimidone (MLR 1023)

Cat. No. A12417 CAS 41964-07-2
MLR 1023 is a selective allosteric activator of Lyn kinase (EC50 = 63 nM)

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Lyn kinase EC50 63 nM

Tolimidone (MLR 1023) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Tolimidone (MLR 1023) from 3 published references. In vitro models include HAMON. In vivo models include groups of 11 female C57BL/6N mice.

Tolimidone (MLR 1023) In Vitro Studies

In NECTIN4 siRNA-transfected HAMON cells, Tolimidone significantly increased the number of live cells compared with NECTIN4 siRNA-transfected, DMSO-treated cells. In human adipocytes, Tolimidone significantly upregulated mitochondrial thermogenesis (UCP1) compared with untreated adipocytes. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tolimidone and viable cells in HAMON cultures

Cell-based study · HAMON [1]

NECTIN4 siRNA-transfected HAMON cells were exposed to Tolimidone. The number of live cells was significantly increased compared with NECTIN4 siRNA-transfected, DMSO-treated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of viable cellsReported result the number of live cells was significantly increased compared with NECTIN4 siRNA-transfected, DMSO-treated cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Method
exposed to
Vehicle
DMSO
Co-treatment
Other interventions in this design: NECTIN4 siRNA. Compound effect isolated by the comparison: NECTIN4-siRNA transfected DMSO-treated cells and NECTIN4-siRNA transfected MLR-1023-treated cells.
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: Tolimidone; Compound label in the paper: MLR-1023

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effects of Src signaling reactivation in NECTIN4-knockdown angiosarcoma cells. (S83); Methods > Reagents (S104); Methods > siRNA transfection (S115); Methods > Cell proliferation assay (S124, S126); Figure 6 legend (S249, S252)

number of viable cells: number of viable cells; comparator: NECTIN4 siRNA-transfected, DMSO-treated cells — Results > Effects of Src signaling reactivation in NECTIN4-knockdown angiosarcoma cells. (S83); Figure 6 legend (S249)

Tolimidone Effects on Thermogenesis in Human Adipocytes

Cell-based study · human adipocytes (HASCs); three obese donors (four technical replicates each) [2]

In human adipocytes, Tolimidone treatment at 60 µM significantly upregulated mitochondrial thermogenesis (UCP1) compared with untreated adipocytes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mRNA expression; qRT-PCR; mitochondrial thermogenesis (UCP1)Reported result MLR-1023 (60 µM) treatment of HASCs for seven days: mitochondrial thermogenesis (UCP1) significantly upregulated compared to untreated adipocytes (control).[2]

Literature-Reported Treatment Conditions

Treatment concentration
60 µM
Exposure duration
for seven days
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Tolimidone; Compound label in the paper: MLR-1023

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. MLR-1023 Increases the Expression of Genes for Thermogenesis and Glucose Utilization in Human Adipocytes (S12); 4. Materials and Methods > 4.7. Human Adipocyte Cell Culture Studies (S78); Figure 4 legend (S111)

mRNA expression; qRT-PCR; mitochondrial thermogenesis (UCP1): mRNA expression; qRT-PCR; mitochondrial thermogenesis (UCP1); comparator: untreated adipocytes (control) — 2. Results > 2.2. MLR-1023 Increases the Expression of Genes for Thermogenesis and Glucose Utilization in Human Adipocytes (S12); Figure 4 legend (S111)

Tolimidone (MLR 1023) In Vivo Studies

In female mice, intraperitoneal Tolimidone administration reduced IAV-induced weight loss and mortality compared with vehicle controls. In db/db male mice, daily intraperitoneal Tolimidone treatment reduced fasting plasma glucose compared with vehicle, with a reduction also observed after treatment ended. [3,2]

Tolimidone Effects on Weight Loss and Mortality Following IAV Infection

Animal study · Groups of 11 female C57BL/6N mice [3]

In female mice, intraperitoneal Tolimidone administration reduced weight loss and mortality induced by IAV infection compared with vehicle controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
survivalReported result MLR-1023 administration (25 and 50 mg/kg/day) reduced the weight loss and mortality induced by IAV infection compared to vehicle controls.[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
from 7 days before challenge and administered for 14 days, once daily
Vehicle
10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tolimidone 25 and 50 mg/kg/dayvehicle controlsMLR-1023 administration (25 and 50 mg/kg/day) reduced the weight loss and mortality induced by IAV infection compared to vehicle controls.[3]
Tolimidone 25 and 50 mg/kg/day
Model: Groups of 11 female C57BL/6N mice
Methods and source locations

Compound reported in the paper: Tolimidone; Compound label in the paper: MLR-1023

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > The kinase activity of LYN is essential to restrict IAV replication (S34); MATERIALS AND METHODS > Mouse study (S154); Fig 3 legend (S262, S263, S264)

survival: survival; comparator: vehicle controls — RESULTS > The kinase activity of LYN is essential to restrict IAV replication (S34); Fig 3 legend (S264)

Tolimidone 25 and 50 mg/kg/day · RESULTS > The kinase activity of LYN is essential to restrict IAV replication (S34); Fig 3 legend (S263)

Tolimidone Effects on Fasting Plasma Glucose in Diabetic Mice

Animal study · db/db male mice (BKS Cg- + Leprdb/ + Leprdb/OlaHsd); N = 18 per group for eight weeks and N = 8 for weeks 9 and 10 [2]

In db/db male mice, daily intraperitoneal Tolimidone treatment at 100 mg/kg reduced fasting plasma glucose compared with vehicle. Reduced fasting plasma glucose was also observed after treatment ended.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fasting plasma glucose (FPG)FPG 100 mg/kg; at eight weeks: difference: −105.2 ± 33.58 mg/dL[2]

Conditions shared by the study groups

Route
IP
Treatment course
once daily; for 56 days
Vehicle
2-hydroxypropyl-beta-cyclodextrin (20%)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tolimidone 100 mg/kgvehicleCompared to the vehicle, MLR-1023 (100 mg/kg) reduced FPG at eight weeks (difference: −105.2 ± 33.58 mg/dL, p = 0.004) and one week after treatment ended (difference: −150.6 ± 44.55 mg/dL, p = 0.005).[2]
Tolimidone 100 mg/kg
Model: db/db male mice (BKS Cg- + Leprdb/ + Leprdb/OlaHsd); N = 18 per group for eight weeks and N = 8 for weeks 9 and 10
Methods and source locations

Compound reported in the paper: Tolimidone; Compound label in the paper: MLR-1023

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.5. In Vivo, Menthol Potentiates the Glucose-Lowering Effect of MLR-1023 (S34, S35); 4. Materials and Methods > 4.2. Animal Studies (S48); 4. Materials and Methods > 4.3. Drug Administration (S52); 4. Materials and Methods > 4.6. Fasting Plasma Glucose Measurement (S66, S67); Figure 8 legend (S128)

Fasting plasma glucose (FPG): Fasting plasma glucose (FPG); comparator: vehicle — 2. Results > 2.5. In Vivo, Menthol Potentiates the Glucose-Lowering Effect of MLR-1023 (S34, S35)

Tolimidone 100 mg/kg · 2. Results > 2.5. In Vivo, Menthol Potentiates the Glucose-Lowering Effect of MLR-1023 (S35); 4. Materials and Methods > 4.6. Fasting Plasma Glucose Measurement (S66, S67)

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 41964-07-2
Formula C11H10N2O2
Molecular Weight 202.21
Synonyms MLR1023
SMILES
CC1=CC(=CC=C1)OC2=CNC(=O)N=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 38 mg/mL (187.92 mM)
Water Insoluble
Ethanol 22 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5%dmso+95%corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tolimidone (MLR 1023) Research References

  1. [1] Tanaka Y, Murata M, Tanegashima K, et al. Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma. Sci Rep (2022). PMID: 35256687 DOI: 10.1038/s41598-022-07727-x Source material
  2. [2] Rebello CJ, Coulter AA, Reaume AG, et al. MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. Pharmaceuticals (Basel) (2021). PMID: 34832978 DOI: 10.3390/ph14111196 Source material
  3. [3] Liu J, Huang J, Wang Q, et al. Tyrosine kinase LYN restricts the replication and virulence of influenza A virus by directly phosphorylating viral nucleoprotein. mBio (2026). PMID: 41910156 DOI: 10.1128/mbio.03759-25 Source material

Added to your cart

View Cart Checkout
Loading...